BioVersys: From Private to Public – How Listing is Expediting Growth and Innovation

A year ago BioVersys, a leading Swiss bio-pharmaceuticals company, went public on SIX Swiss Exchange. We sat down with BioVersys’ CEO and Founder Marc Gitzinger to discuss how SIX Swiss Exchange supported the company on its path to the IPO - and how BioVersys benefits from being a listed public company ever since.

BioVersys: From Private to Public – How Listing is Expediting Growth and Innovation

About BioVersys

Based in Basel, Switzerland, BioVersys is a leading Swiss bio-pharmaceuticals company specialising in the research and development of novel anti-bacterial products for life threatening infections caused by multi-drug resistant bacteria. These include BV100 and Alpibectir, two drug candidates which address two of the top three priorities of the World Health Organisation for bacterial pathogens to prevent a global health crisis. 

BioVersys’ IPO in February 2025 kicked off the IPO season on SIX Swiss Exchange. The IPO raised CHF 80 million and provided the company with an excellent springboard for future growth.  

 

Porträt von Jürg Stalder, Leiter Tax & Regulatory Products, mit einem Zitat über das Einliefern von Klarheit und Deckung bei der Navigation durch FATCA- und 1446(f)-Regelungen, das eine vereinfachte Klassifizierung, Meldung und Compliance über die US-Steuersysteme hinweg sicherstellt.

It was a very emotional day and a big milestone for the company. We gained a lot of public visibility. It was also an important milestone for our different stakeholders and shareholders, as we demonstrated that the company has continued to mature.

Marc Gitzinger CEO and founder of BioVersys

 

SIX Swiss Exchange has supported BioVersys at every step of its IPO journey.

“The IPO Academy was incredibly helpful. It provides you with invaluable contacts of people who work in an IPO environment, and prepares you for what to expect, both during the IPO process and what happens afterwards. For us, the programme was really valuable, and I would absolutely recommend it to any company that is serious about going public,” said Gitzinger. 

 

The Message from BioVersys

Being a publicly listed biotech company on SIX Swiss Exchange provides access to a diverse range of investors, who provide companies – such as BioVersys – with the funding required to fuel expansion and research and development.

“Following the listing, our visibility has increased significantly. As a result, we have gained new, important shareholders. Broadening our shareholder base was an important criterium for listing. The ultimate goal of this IPO was to raise the funds so that we can develop our products towards the final stages of development and phase three clinical trials, the IPO is enabling BioVersys to push ahead at full speed with its various clinical trials and exciting pipeline of drug candidates.” said Gitzinger in an interview conducted in September 2025.

 

 

On 7 February 2026, BioVersys AG marked one year since its listing on SIX Swiss Exchange - strengthening Switzerland’s role as a leading hub for biotech innovation. 

CEO Marc Gitzinger reflects on a year defined by scientific progress, greater global visibility, improved access to capital, and key milestones incl. momentum across partnerships and advancing BV100 into a global Phase 3 trial.

 

About Marc Gitzinger

CEO and Founder of BioVersys. Gitzinger has many years’ experience in the biotech industry, having launched a university spinoff in the field of antimicrobial resistance and transformed it into a multi-asset clinical stage company. He is also President of the Board of the BEAM Alliance, a European association representing over 70 European and international SMEs active in antimicrobial research and development.

Listing on SIX Swiss Exchange

With SIX Swiss Exchange by your side, the path from IPO to everyday life as a listed company is clear and straightforward. Learn more about going public on SIX Swiss Exchange and discover Sparks, our segment for SMEs.

Learn more